Valnoctamide (VCD), an over-the-counter tranquilizer which displays anticonvulsant activity in animal models was added at a daily dosage of 600 mg to six epileptic patients on carbamazepine (CBZ) therapy. During VCD treatment the serum levels of the active CBZ metabolite, i.e. CBZ-Epoxide, increased 5-fold on average (from 1,5 ± 0,7 μg/ml to 7,4 ± 4,4 μg/ml). In four patients this rise was associated with clinical signs of CBZ intoxication. In preparations of human liver microsomes VCD at therapeutic concentration inhibited the hydrolysis of styrene-oxide. Thus VCD is a potent inhibitor of the enzyme epoxide-hydrolase (IC50 = 15 μM).
|Translated title of the contribution||Interaction of Carbamazepine with Valnoctamide: Data 'in vitro' and in patients with epilepsy|
|Number of pages||1|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Clinical Neurology